News

YM BioSciences and Therapure Biopharma have entered into a service agreement, where by Therapure Biopharma will provide fill and finish services for Nimotuzumab, the humanized monoclonal antibody licensed

Mettler Toledo (Mettler) has reported that it was approached by a major gelatin capsule manufacturer to optimise its capsule counting system. The company was selected by its customer’s

Ipsen has announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for Taspoglutide,

Cyanotech has launched new products for its Nutrex-Hawaii brand that target specific demographics and nutritional goals. The 100% vegetarian products are based on the company’s Hawaiian Spirulina Pacifica,

Durect has presented positive results from a 60 patient Phase IIb clinical trial of Posidur, a proprietary product under development for the treatment of post-surgical pain. Top line

Cell Therapeutics (CTI) has reported that on February 10, 2010, the FDA’s Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for Pixantrone, for the

NovaBay Pharmaceuticals (NovaBay) has reported that its partner, Alcon has increased its on-going financial support of the company’s research and development efforts by more than $2m per year.

The US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for LifeCycle Pharma’s (LCP) patent application directed to its fenofibrate tablet. The patent application covers

Forest Laboratories and Almirall have entered into an agreement to develop, market and distribute LAS100977 in the US. LAS100977 is an inhaled, once-daily administered long-acting beta2 agonist (LABA),